Where the Evidence Travels—and Where It Stops
Doxy-PEP raises a question that resistance data alone cannot answer: how far can evidence from one population and care setting travel to another? The focus here is the boundary between biological plausibility and demonstrated clinical benefit, especially the contrast between the populations represented in the strongest trials and the Kenyan trial among cisgender women. That distinction helps readers interpret current WHO and CDC guidance without turning a population-specific recommendation into either a universal rule or a claim that the intervention cannot work elsewhere.
The recommendation follows the evidence base
The strongest randomized evidence for doxy-PEP comes from men who have sex with men and transgender women at elevated risk of bacterial STIs. That description contains more than an identity label. The trials involved particular sexual behaviors, exposure networks, prior STI histories, prevention contexts and follow-up arrangements. These features help determine the probability of exposure, the infections being observed and the practical value of the intervention.
WHO’s current recommendation is conditional: doxy-PEP may be offered to men who have sex with men and transgender women for prevention of bacterial STIs. WHO gives priority to those with a recent or recurrent STI—especially syphilis—and to people in high-incidence sexual networks or settings. The recommendation is not a promise that everyone in the named population receives the same absolute benefit. It is a policy position that combines the observed efficacy with uncertainty about antimicrobial resistance, longer-term effects, resources, equity and implementation.
CDC frames the clinical conversation somewhat differently. It recommends that providers counsel gay, bisexual and other men who have sex with men and transgender women with at least one bacterial STI—syphilis, chlamydia or gonorrhoea—diagnosed during the previous 12 months about the benefits and harms of doxy-PEP. After shared decision-making, providers should offer the intervention to this group. CDC also says that doxy-PEP could be discussed with men who have sex with men and transgender women without a bacterial STI in the previous year if their planned sexual activity is known to increase the likelihood of STI exposure, although those people were not directly assessed in the trials used for the recommendation.
These formulations are not best understood as competing verdicts. WHO emphasizes a population-level offer with prioritization according to recent infection and local incidence. CDC gives clinicians a concrete recent-STI trigger for counseling and an explicit shared-decision process, while allowing discussion in some additional high-exposure circumstances. Both preserve the same underlying boundary: the strongest evidence is concentrated in a defined population, and use should be risk-aware rather than population-wide by default.
The boundary does not mean that doxycycline suddenly loses all biological activity when a person falls outside a trial category. CDC notes that pharmacokinetics and experience treating bacterial STIs suggest doxy-PEP could be effective in other populations, but clinical data are limited for cisgender women, cisgender heterosexual men, transgender men and other queer and nonbinary people assigned female at birth. WHO likewise does not currently recommend doxy-PEP for other populations.